EP-SOGO

EP-SOGO trends of drug development are shifting from lifestyle diseases to cancer, CNS, and rare diseases. Furthermore, new types of drugs embracing cell and gene technologies are emerging. The protocols of these studies are difficult .complicated than conventional studies. Accordingly, a higher level of expertise is required of CRCs. To accommodate these changes, they are making further efforts to intensively improve the proficiency of their CRCs with disease training by external trainers and p... articipation in domestic and overseas conferences. In addition, clinical trial processes are also undergoing significant changes. The revision of ICH-E6 is requiring the efficiency improvement of control systems. On of this, the industry accelerated the effort to streamline clinical trial operations as the COVID-19 pandemic restricted physical contacts in trial activities. Their corporate philosophy is “If they improve each day, they can progress themselves daily, and will continue to do so. Ever progressing system. Based on this philosophy, they will collaborate with EPS group company affiliates ”. Additionally, for EP-SOGO, “New Creation” is to provide ever-progressing services while maintaining core. Everyone at EP-SOGO has stepped forward to work together on “New Creation”. With a strong sense of responsibility and a firm commitment to healthcare in Japan, hoping that new drugs reach patients as early as possible and that the industry develops further, they would like to progress step by step with, their valued customers.More